Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.

PMID:
22908275
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
[PubMed - indexed for MEDLINE]
3.

Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR.

Nature. 2004 Sep 30;431(7008):525-6.

PMID:
15457249
[PubMed - indexed for MEDLINE]
4.

ERBB2 kinase domain mutation in the lung squamous cell carcinoma.

Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Wang YP, Jo KH, Moon SW, Song SY, Lee JY, Yoo NJ, Lee SH.

Cancer Lett. 2006 Jun 8;237(1):89-94. Epub 2005 Jul 18.

PMID:
16029927
[PubMed - indexed for MEDLINE]
5.

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.

Cancer Res. 2006 Jul 1;66(13):6487-91.

PMID:
16818618
[PubMed - indexed for MEDLINE]
Free Article
6.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
[PubMed - indexed for MEDLINE]
7.

EGFR and erbB2 mutation status in Japanese lung cancer patients.

Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, Matsumura A, Iuchi K, Haneda H, Suzuki E, Kobayashi Y, Yano M, Fujii Y.

Int J Cancer. 2006 Jan 1;118(1):180-4.

PMID:
16003726
[PubMed - indexed for MEDLINE]
8.

Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.

Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y, Kanakura Y.

Blood. 1999 Feb 15;93(4):1319-29.

PMID:
9949175
[PubMed - indexed for MEDLINE]
Free Article
9.

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS.

Clin Cancer Res. 2008 Apr 15;14(8):2465-75. doi: 10.1158/1078-0432.CCR-07-4367.

PMID:
18413839
[PubMed - indexed for MEDLINE]
Free Article
10.

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.

Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M.

Cancer Biol Ther. 2007 May;6(5):661-7. Epub 2007 Feb 13.

PMID:
17495523
[PubMed - indexed for MEDLINE]
Free Article
11.

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK.

Oncogene. 2007 Jul 26;26(34):5023-7. Epub 2007 Feb 19.

PMID:
17311002
[PubMed - indexed for MEDLINE]
12.

Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.

Fan YX, Wong L, Ding J, Spiridonov NA, Johnson RC, Johnson GR.

J Biol Chem. 2008 Jan 18;283(3):1588-96. Epub 2007 Nov 26.

PMID:
18039657
[PubMed - indexed for MEDLINE]
Free Article
13.

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.

Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, Gerald WL, Pincus MR, Osman I, Lee P.

Oncogene. 2008 May 15;27(22):3201-10. doi: 10.1038/sj.onc.1210983. Epub 2008 Jan 14.

PMID:
18193092
[PubMed - indexed for MEDLINE]
14.

Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.

Bourguignon LY, Gilad E, Peyrollier K.

J Biol Chem. 2007 Jul 6;282(27):19426-41. Epub 2007 May 10.

PMID:
17493932
[PubMed - indexed for MEDLINE]
Free Article
15.

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK.

PLoS Med. 2006 Dec;3(12):e485.

PMID:
17177598
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.

Oncogene. 2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14.

PMID:
18408761
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The ErbB/HER receptor protein-tyrosine kinases and cancer.

Roskoski R Jr.

Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11. Review.

PMID:
15158434
[PubMed - indexed for MEDLINE]
18.

177Lu-Labeled humanized monoclonal antibody against human epidermal growth factor receptor 2.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Nov 17 [updated 2008 Dec 17].

PMID:
20641866
[PubMed]
Books & Documents
19.
20.

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.

Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, Shigematsu H, Kuwano H, Yatabe Y, Mitsudomi T.

Lung Cancer. 2011 Oct;74(1):139-44. doi: 10.1016/j.lungcan.2011.01.014. Epub 2011 Feb 25.

PMID:
21353324
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk